Car-t cell therapy for severe autoimmune hemolytic anemia
Part of Blood & lymphatic, Immune system & allergy clinical trials.
This trial tests a new type of cell therapy (called CAR-T) for people with autoimmune hemolytic anemia or Evans syndrome that has not improved with standard treatments. The goal is to see if this therapy can control the condition and reduce the need for ongoing immune-suppressing drugs.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have a confirmed diagnosis of autoimmune hemolytic anemia (AIHA) or Evans syndrome, including types like warm antibody or cold agglutinin disease.
- Your disease has not responded to or has come back after at least two different immune-suppressing treatments, including rituximab (a common drug for AIHA).
- Your hemoglobin level is below 10 g/dL (meaning you have significant anemia causing symptoms).
- You have been on steroid treatments (like prednisone) for at least 3 months, unless you cannot take them due to medical reasons.
- Your overall health is good enough to participate, as measured by a simple performance score (ECOG 0-2).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of immunotherapy called CAR T-cell therapy that targets two markers on your immune cells (CD19 and BCMA). It is for people with autoimmune hemolytic anemia (AIHA) who have already tried at least 3 standard treatments without success.
This study tests an experimental cell therapy called YTS109 for people with autoimmune hemolytic anemia (AIHA) or Evans syndrome that has not improved with standard treatments. The goal is to see if this therapy can help control the anemia and reduce the need for ongoing treatments.
This early-stage trial tests a new type of immune cell therapy (CAR-T) that targets two proteins, CD19 and BCMA, in people with autoimmune blood diseases like ITP, AIHA, or Evans syndrome that have not responded to standard treatments. It aims to reset the immune system and reduce production of harmful antibodies.
This study tests a new cell therapy called YTS109 for people with autoimmune hemolytic anemia that hasn't improved after other treatments. The goal is to see if this therapy can help control the disease and be safe.
This trial tests a new medicine for people with autoimmune hemolytic anemia (AIHA) that has not improved with standard treatments. The goal is to see if the drug can help control the disease and improve red blood cell counts.
This trial tests a new cell treatment called YTS109 for people with autoimmune hemolytic anemia (AIHA) that has not improved after several standard treatments. The goal is to see if this treatment can help control the disease.
Hear when a new Autoimmune Hemolytic Anemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.